OR WAIT null SECS
North Estonia Medical Centre (NEMC) consists of seven clinics and 32 specialist centers, and is the most important caregiver in the capital of Estonia, Tallinn, as well as in the northern part of the country. As a tertiary care center, it covers two thirds of the population of Estonia. NEMC’s team has over 4000 doctors, nurses, caregivers and other specialists. Over 500 of them are doctors and more than 150 are medical residents.
During 2017, about 35,000 inpatients and 306,000 outpatients were treated on 1,146 beds (52 ICCU/ICU beds) and about 27,700 operations were performed.
NEMC is a leading hospital in acute cardiac care, having the highest number of acute myocardial infarction patients treated among Estonian hospitals, offering 24/7 primary PCI service.
NEMC has a leading expertise in clinical trials in Estonia, where continuous education programs about GCP and clinical trials methodology have been provided for many years for different target groups – investigators, pharmacists, nurses and study coordinators. The first courses specifically for nurses and refresher courses for experienced investigators in Estonia were started at NEMC.
NEMC currently runs about 85 clinical trials per year, 25 of them begun in 2018, with the capacity and expertise to run many more. By joining the Patient Network Explorer platform, the hospital’s clinical trials facilities will be exposed to a wide range of global clinical trials run by Clinerion’s clients, international pharmaceutical companies and contract research organizations.
“We expect significant increase our visibility on international level and access to many more different international research projects in the next years. I hope that this collaboration will open doors to innovative new treatments for our patients and give our colleagues the opportunity to participate in R&D activities from earlier phases of clinical trials,” says clinical pharmacologist and senior cardiologist Dr Toomas Marandi.
“We are thrilled to have the North Estonia Medical Centre on the Patient Network Explorer platform. It’s a sign of the trust and success of our approach that Clinerion now has coverage over a significant part of Estonia,” says Ian Rentsch, CEO of Clinerion. “We welcome the high professionalism and strong medical expertise of the NEMC.”
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
Clinerion website: www.clinerion.com
Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer
For more information, please contact:
Le Vin Chin
Director, Head of Marketing & Communications
Elisabethenanlage 11, 4051 Basel, Switzerland
Tel.: +41 61 865 60 54